Slide 1: Interim Report Fourth Quarter & Year End 2024
Interim Report Fourth Quarter & Year End 2024 February 21, 2025
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: Opening Remarks
OPENING REMARKS Magnus Persson Chairman of the Board of Directors
Slide 4: Q4 & Year End Report
Q4 & YEAR END REPORT Damian Marron Interim Chief Executive Officer
Slide 5: Events in the Fourth Quarter and After the Period
Events in the Fourth Quarter and After the Period Significant Events in the Fourth Quarter 2024 • Cantargia reported new positive results regarding biomarkers and safety from the ongoing clinical phase 1 study with CAN10. • New results from the clinical studies CESTAFOUR and CAPAFOUR, where nadunoli
Slide 6: CAN10 – Opportunity in Autoimmune/Inflammatory Disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 7: CAN10 First-in-Human study
CAN10 First-in-Human study Additional MAD cohorts added in Q4 2024 7
Slide 8: CAN10 first-in-human study - SAD part
CAN10 first-in-human study - SAD part Design Results • Blinded, placebo-controlled study • No safety signals • Nine dose groups from 1 to 400 mg CAN10 incl. 2 patients on • Receptor occupancy documented (at Cmax) placebo in each group • Potent PD effects on IL-1 & IL-36 at Cmax and day 8 Receptor Oc
Slide 9: Initial Indication - Hidradenitis Suppurativa (HS)
Initial Indication - Hidradenitis Suppurativa (HS) HS – a severe chronic inflammatory skin disease • HS is a diverse disease with several inflammatory components involved in the pathology • Estimated HS prevalence of 0.7-1.2% Inadequate current treatments • Antibiotics • Steroids • Anti-TNFα (Humira
Slide 10: Preparing for Phase 2 in HS
10 Preparing for Phase 2 in HS IL-1 receptor complex IL-33 receptor complex IL-36 receptor complex ILIRAP/IL1R3 ILIR1 ST2 CAN10 CAN10 niin Mw ILRrP2 CAN10 oan @antargia
Slide 11: Nadunolimab
NADUNOLIMAB
Slide 12: Nadunolimab Summary
Nadunolimab Summary • Published results in PDAC, confirming very strong benefit in patients with high IL1RAP • Diagnostic tests in development – will enable continued development in subgroup. We are planning for a regulatory interaction. • Reported results from CESTAFOUR and CAPAFOUR with positive s
Slide 13: PDAC: Efficacy and IL1RAP levels on tumor cells
Van Cutsem et al, Clinical Cancer Research 2024 PDAC: Efficacy and IL1RAP levels on tumor cells OS by IL1RAP subgroup IL 1 R A P H ig h IL 1 R A P L o w 50% Best change in tumor size 0% iCPD iUPD iSD -50% iPR -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients → High IL
Slide 14: Milestones
MILESTONES
Slide 15: Upcoming milestones
Upcoming milestones 2025 Q1 Q2 Q3 Q4 PDAC Regulatory Update TRIFOUR recruitment Nadunolimab TNBC completed TRIFOUR initial results Study start with AML DoD/MD Anderson* Phase 2 start in Initial Phase 1 MAD Phase 1 MAD study CAN10 results completed Hidradenitis Suppurativa Other Additional new precli
Slide 16: Financial Results
FINANCIAL RESULTS Patrik Renblad Chief Financial Officer
Slide 17: Financial Highlights – as of December 31, 2024
Financial Highlights – as of December 31, 2024 R&D Expenses G&A & OOI/OOE Reported loss for the period SEK 36.6m SEK 4.1m SEK 39.4m Q4 (Q4 2023: SEK 68.0m) (Q4 2023: SEK 3.1m) (Q4 2023: SEK 71.3m) Reduction of ~46%, reflecting fewer clinical studies G&A amounted to SEK 3.9m (SEK 3.5m) in the Operati
Slide 18: Cash Flow and Cash Position
Cash Flow and Cash Position MSEK Operating Cash Outflow 195 SEK 26.3m (December 31, 2023: SEK 56.5m) 143 140 Available funds 140 105 SEK 33.0m 108 107 (December 31, 2023: SEK 194.7m) 60 85 33 Rights Issue 2024 55 60 35 33 33 • The outcome of the 2024 rights issue was 20 0 0 0 confirmed by year-end b
Slide 19: Closing Remarks and Q&A
CLOSING REMARKS AND Q&A